FULC
Fulcrum Therapeutics Inc.
$8.47
-$0.55(-6.15%)
52
Overall
60
Value
50
Tech
47
Quality
Market Cap
$540.92M
Volume
413.61K
52W Range
$2.32 - $10.11
Target Price
$13.00
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | -- | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | ||
| Total Revenue | -- | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | ||
| GROSS PROFIT | ||||||||
| Gross Profit | -- | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $-84.2M | $80.4M | $100.2M | $118.9M | $113.5M | $101.9M | ||
| Research & Development | $71.1M | $59.0M | $69.7M | $76.8M | $71.8M | $63.4M | ||
| Research Expense | $71.1M | $59.0M | $69.7M | $76.8M | $71.8M | $63.4M | ||
| Selling, General & Administrative | $13.1M | $21.4M | $30.5M | $41.7M | $41.7M | $36.4M | ||
| General & Administrative Expenses | $13.1M | $21.4M | $30.5M | $41.7M | $41.7M | $36.4M | ||
| Salaries & Wages | $-4.2M | $7.3M | $11.1M | $13.3M | -- | -- | ||
| Depreciation & Amortization | $-2.1M | $2.4M | $2.5M | $2.4M | $2.2M | $1.6M | ||
| Depreciation & Amortization | $-2.1M | $2.4M | $2.5M | $2.4M | -- | -- | ||
| Other Operating Expenses | -- | -- | $1.9M | $1.9M | -- | -- | ||
| OPERATING INCOME | ||||||||
| Operating income | $-84.2M | $-71.6M | $-81.1M | $-112.6M | $-110.7M | $-21.9M | ||
| EBITDA | $-80.6M | $-69.2M | $-78.5M | $-109.7M | $-95.2M | $-8.1M | ||
| NON-OPERATING ITEMS | ||||||||
| Intinc | $1.5M | $792.0K | $207.0K | $2.7M | $13.3M | $12.2M | ||
| Net Non-Operating Interest Income/Expense | $1.5M | $792.0K | $207.0K | $2.7M | $13.3M | $12.2M | ||
| Other Income/Expense | $-29.0K | -- | -- | $2.3M | $13.3M | -- | ||
| Other Special Charges | $29.0K | -- | -- | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||
| Restructring And Mn A Income | -- | -- | -- | $427.0K | -- | $2.1M | ||
| Special Income Charges | -- | -- | -- | $-427.0K | -- | $-2.1M | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-82.7M | $-71.6M | $-81.1M | $-112.1M | $-97.3M | $-9.7M | ||
| Pre-Tax Income | $-82.7M | $-70.8M | $-80.8M | $-109.9M | $-97.3M | $-9.7M | ||
| NET INCOME | ||||||||
| Net Income | $-82.7M | $-70.8M | $-80.8M | $-109.9M | $-97.3M | $-9.7M | ||
| Net Income (Continuing Operations) | $-82.7M | $-70.8M | $-80.8M | $-109.9M | $-97.3M | $-9.7M | ||
| Net Income (Discontinued Operations) | $-82.7M | $-70.8M | $-80.8M | $-109.9M | $-97.3M | $-9.7M | ||
| Net Income (Common Stockholders) | $-89.8M | $-70.8M | $-80.8M | $-109.9M | $-97.3M | $-9.7M | ||
| Normalized Income | -- | -- | $-63.9M | -- | -- | -- | ||
| TOTALS | ||||||||
| Total Expenses | $-84.2M | $80.4M | $100.2M | $118.5M | $113.5M | $101.9M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $11.0K | $25.4K | $35.4K | $45.0K | $61.3K | $62.0K | ||
| Average Shares Outstanding (Diluted) | $10.2M | $25.4K | $35.4K | $45.0K | $61.3K | $62.0K | ||
| Shares Outstanding | $23.4M | $32.7M | $40.6M | $61.8M | $54.1M | $54.1M | ||
| Basic EPS | -- | $-2.79 | $-2.29 | $-2.44 | $-1.59 | $-0.16 | ||
| Basic EPS (Continuing Operations) | -- | $-2.79 | $-2.29 | $-2.44 | $-1.59 | $-0.16 | ||
| Diluted EPS | $-8.13 | $-2.79 | $-2.29 | $-2.44 | $-1.59 | $-0.16 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-2.44 | $-1.59 | $-0.16 | ||
| OTHER METRICS | ||||||||
| Accrued Preferred Stock Dividends | $7.1M | -- | -- | -- | -- | -- | ||
| Other Gand A | $13.1M | $21.4M | $30.5M | $41.7M | $41.7M | $36.4M | ||
| Otherunder Preferred Stock Dividend | $7.1M | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $7.1M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $13.1M | -- | $100.0K | -- | -- | -- | ||
| Restruct | -- | -- | -- | $427.0K | -- | $2.1M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FULC | $8.47 | -6.2% | 413.61K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Fulcrum Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW